Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Metastatic Cancer Pancreas Clinical Trial

Official title: PHASE 1/2 STUDY OF PF-03084014 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Status Terminated

Clinical Trial Summary

This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Cancer Pancreas
• Neoplasm Metastasis

• NCT number: NCT02109445
• Study type: Interventional
• Source: Pfizer
• Status: Terminated
• Phase: Phase 2
• Start date: September 3, 2014
• Completion date: November 6, 2014